Camrelizumab plus chemotherapy extends survival in advanced squamous NSCLC
In short: A phase 3 trial of 389 patients with advanced squamous NSCLC found that camrelizumab plus chemotherapy significantly improved progression-free survival and overall survival compared to placebo plus chemotherapy.
The study was a double-blind, randomized trial conducted in China. Patients received camrelizumab or placebo with chemotherapy, followed by maintenance therapy. ctDNA levels were monitored to predict treatment response. The study showed that camrelizumab improved survival, but results are based on a single trial and may not apply globally.
Why it matters: Camrelizumab plus chemotherapy may be an effective first-line treatment for advanced squamous NSCLC.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Ren et al. (2022). Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
To cite this card, link to https://intellectplus.co.uk/app/health-research-camrelizumab-plus-chemotherapy-extends-survival-in-advanced.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
